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Introduction: As more infants are surviving at younger gestational ages, bronchopul-
monary dysplasia (BPD) remains as a frequent neonatal complication occurring after
preterm birth. The multifactorial nature of the disease process makes BPD a challenging
condition to treat.While multiple pharmacologic therapies have been investigated over the
past two decades, there have been limited advances in the ﬁeld. Often multiple therapies
are used concurrently without clear evidence of efﬁcacy, with potential for signiﬁcant side
effects from drug-drug interactions.
Methods: Systematic literature review.
Conclusion:Although there is physiologic rationale for the use of many of these therapies,
none of them has single-handedly altered the incidence, severity, or progression of BPD.
Future research should focus on developing clinically signiﬁcant end-points (short and long
term respiratory assessments), investigating biomarkers that accurately predict risk and
progression of disease, and creating appropriate stratiﬁcation models of BPD severity.
Applying a multi-modal approach to the study of new and existing drugs should be the most
effective way of establishing the optimal prevention and treatment regimens for BPD.
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INTRODUCTION
Bronchopulmonary dysplasia (BPD) has been traditionally
deﬁned as a chronic form of lung disease in neonates treated with
oxygen and positive pressure ventilation for a primary lung disor-
der. As more neonates at the threshold of viability are surviving,
BPD continues to be a persistent and prevalent NICU morbid-
ity with approximately 15,000 neonates diagnosed in the United
States each year. BPD also carries a higher risk of neurodevelop-
mental morbidity and (Ehrenkranz et al., 2005) mortality, making
it an extremely important complication of neonatal intensive care.
Bronchopulmonary dysplasia was ﬁrst described by Northway
et al. (1967) as chronic lung disease that developed in premature
infants who were ventilated with high pressures and concentra-
tions of oxygen. The histological appearance was characterized by
parenchymal ﬁbrosis, inﬂammation, and smooth muscle hyper-
trophy resulting in diffuse airway damage (O’Brodovich and
Mellins, 1985). However, the nature of BPD has evolved into
a “new” form of BPD typically seen in neonates surviving at
the threshold of viability and characterized primarily by arrest
of alveolar and vascular development (Husain et al., 1998; Jobe,
1999; Jobe and Bancalari, 2001; Baraldi and Filippone, 2007).
The deﬁnition of BPD has also changed over time, with an NIH
consensus conference capturing criteria from previous deﬁnitions
and incorporating a stratiﬁcation system based on clinical sever-
ity (Jobe and Bancalari, 2001; Table 1). Since the pathogenesis
of BPD is multifactorial (e.g., mechanical ventilation, oxygen
exposure, nutritional deﬁcits, fetal growth restriction, and genetic
susceptibility), a multidisciplinary approach is necessary for effec-
tive treatment. This article will discuss current pharmacologic
approaches, which have not changed dramatically in the last
20 years. Often, many of these therapies are used concurrently
with inadequate studies to deﬁne efﬁcacy as well as the poten-
tial for signiﬁcant side effects (especially drug-drug interactions).
Finally, experimental agents that are being investigated for the
prevention of BPD and associated complications of this common
neonatal disease will be introduced.
METHODS
Approximately 100 articles, including animal studies, human pilot
studies, randomized controlled trials (RCTs), meta-analyses, and
systematic reviews published on the PubMed database were evalu-
ated for inclusion in this article. Additionally, ClinicalTrials.gov
was queried for ongoing studies investigating pharmacologic
therapies for BPD.
DIURETICS
Large volumes of intravenous ﬂuids are often administered to pre-
mature neonates to provide adequate hydration and nutrition.
Excessive ﬂuid administration can be associated with pulmonary
edema (especiallywith acute lung injury) and lead to increased res-
piratory support and ultimately BPD (Oh et al., 2005). Furosemide
acts on the ascending loop of Henle and blocks chloride trans-
port. Additionally, furosemide decreases interstitial edema and
pulmonary vascular resistance and increases plasma oncotic pres-
sure and lymphatic ﬂow. It is the treatment of choice for ﬂuid
overload in BPD. Several studies have demonstrated alternate-day,
daily, and even aerosolized furosemide improve clinical respiratory
status, pulmonary mechanics, oxygenation, and facilitate weaning
from mechanical ventilation. However, long-term beneﬁts have
not been established in infants with BPD (Rush et al., 1990; Sahni
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Table 1 | NIH severity-based diagnostic criteria for bronchopulmonary
dysplasia (BPD).
Gestational age <32 weeks
Timing of assessment • 36 weeks post-menstrual age (PMA) or
discharge home, whichever comes ﬁrst
•Therapy with oxygen >21% for at least 28 days
plus
Mild BPD Breathing room air
Moderate BPD Need for <30% oxygen*
Severe BPD Need for ≥30% oxygen and/or positive pressure
(PPV or CPAP)*
*A physiologic test conﬁrming an oxygen requirement at the assessment time
point remains to be deﬁned. The test may include a pulse oximetry saturation
range by Jobe and Bancalari (2001).
and Phelps, 2011; Stewart and Brion, 2011; Segar, 2012). Thi-
azides affect the renal tubular excretion of electrolytes but are less
potent than loop diuretics. Potassium and bicarbonate excretion
also occur which has prompted the use of thiazides in conjunction
with spironolactone, a competitive inhibitor of aldosterone. This
weak potassium-sparing diuretic facilitates sodium, chloride, and
water excretion. A small number of controlled trials examining the
use of thiazide diuretics and spironolactone in BPDhave generated
mixed results with urine output increasing, but not always accom-
panied by improvements in pulmonary mechanics (Engelhardt
et al., 1989; Hoffman et al., 2000). The use of spironolactone does
appear to offer any substantial beneﬁt and is not recommended.
Overall, diuretics offer short-term improvements in pulmonary
mechanics but are associatedwith anumber of side effects thatmay
limit longer-term use (e.g., ototoxicity, electrolyte disturbances,
azotemia, etc.). Furthermore, there are limited data demonstrat-
ing signiﬁcant beneﬁts of these agents when more meaningful
outcome measures are analyzed such as reduction in the duration
of mechanical ventilation and hospitalization or improved long-
term clinical outcomes (less asthma, pulmonary infections, etc.).
Additional longer-term studies are needed to establish optimal
treatment regimens in infants with established BPD.
BRONCHODILATORS
Albuterol (also known as ‘Salbutamol’) is an inhaled β2-agonist
that is the recommended for the treatment of BPD with a strong
component of reversible bronchospasm (Davis and Rosenfeld,
2005). It has been associated with short-term improvements in
pulmonary resistance and lung compliance secondary to bronchial
smooth muscle relaxation (Wilkie and Bryan, 1987). While a
Cochrane review examining the role of albuterol was unable to
ﬁnd sufﬁcient evidence of efﬁcacy in the prevention of BPD, other
studies have shown improvement in pulmonary mechanics fol-
lowing treatment (Robin et al., 2004; Ng et al., 2012). In summary,
long-term efﬁcacy has not been established and tolerance may
develop with prolonged use.
Ipratropium bromide is a muscarinic antagonist that produces
bronchodilation in chronically ventilated infants with BPD. Sig-
niﬁcant improvements in airway resistance and compliance has
been shown in its isolated use or combined with a β2-agonist
(Brundage et al., 1990). However, clinical trials have not demon-
strated changes in the natural progression of BPD or long-term
clinical respiratory status (De Boeck et al., 1998; Pantalitschka and
Poets, 2006). Despite these ﬁndings, infantswithBPDwhodevelop
wheezingmay warrant a trial with albuterol initially with the addi-
tion of ipratropium bromide if signiﬁcant side effects occur or
clinical improvement isn’t seen with a β2-agonist alone.
VITAMIN A
Vitamin A (i.e., retinol) is important in maintaining cell integrity
and promoting tissue repair with deﬁciencies producing sig-
niﬁcant changes in the tracheobronchial tree (Anzano et al.,
1980). Multiple studies have demonstrated that very low birth
weight infants are deﬁcient in Vitamin A and at a propensity to
develop BPD (Shenai et al., 1990; Darlow and Graham, 2011). A
landmark, multicenter Neonatal Research Network (NRN) trial
investigated the beneﬁts of vitaminA supplementation in improv-
ing survival without BPD in 807 neonates weighing <1000 g
at birth. Intramuscular doses of 5000 IU of Vitamin A given
three times a week for 4 weeks demonstrated a small (9%),
but signiﬁcant reduction in survival without chronic lung dis-
ease at 36 weeks post-menstrual age (PMA; Tyson et al., 1999).
No increased toxicity was seen with the higher dosing regimen
compared to placebo. However, long-term follow-up of these
infants at 18–22 months could not demonstrate any improvement
in mortality, neurodevelopmental impairment, or respiratory
outcomes from treatment with Vitamin A (Ambalavanan et al.,
2005). However, this study was not powered for demonstrat-
ing differences in these longer-term outcomes, so many centers
still administer vitamin A routinely in infants at high risk for
developing BPD.
METHYLXANTHINES
Caffeine treatment for the prevention of apnea of prematurity
and BPD is currently the standard of care in most neonatal
intensive care units (Ghanta et al., 2013). It has been shown
to increase respiratory drive, diaphragm contractility, and pul-
monary compliance while reducing airway resistance (Davis et al.,
1989; Aranda et al., 2010). These effects are of particular impor-
tance in chronically ventilated neonates who can develop skeletal
muscle and diaphragmatic atrophy and fatigue. The improved
muscle contractilitymay stabilize the chest wall and improve func-
tional residual capacity facilitating successful extubation (Davis
and Rosenfeld, 2005). Schmidt et al. (2006) conducted a large,
multicenter RCT investigating the effects of caffeine on apnea of
prematurity in a cohort of infants weighing 500–1250 g at birth.
While infants in the treatment group had signiﬁcantly less apnea
of prematurity, they were also noted to have less BPD (deﬁned
as need for supplemental oxygen at 36 weeks PMA), patent duc-
tus arteriosus (PDA), and cerebral palsy when followed out to
18–21 months corrected gestational age (Schmidt et al., 2007).
However, these outcomes did not translate into longer-term ben-
eﬁts when this same cohort of infants was examined at 5 years of
age (Schmidt et al., 2012). Despite these ﬁndings, caffeine ther-
apy remains a standard medical approach to the prevention and
treatmentof BPD.
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Pentoxifylline is a methylxanthine derivative and phospho-
diesterase inhibitor with immunomodulatory and anti-ﬁbrotic
properties (Almario et al., 2012; Ghanta et al., 2013). It has
been proposed to have a therapeutic role in attenuating tis-
sue injury associated with sepsis (Harris et al., 2000; Michetti
et al., 2003). In a hyperoxia-induced lung injury model of BPD,
pentoxifylline reduced lung edema and inﬂammatory cell inﬁltra-
tion while improving antioxidant activity, vascular development,
and overall survival (Almario et al., 2012). A RCT in 150 very
low birth weight infants demonstrated a reduction in BPD in
infants receiving pentoxifylline compared to placebo (Ruszard
et al., 2006). However, there is still insufﬁcient evidence to sup-
port widespread usage and further safety and efﬁcacy data is
needed.
CORTICOSTEROIDS
Marked inﬂammation in the lung appears to play an important
role in the pathogenesis of BPD,unifyingmany factors into a single
common pathway. Therefore, it is reasonable to consider the use
of corticosteroids in treating BPD. The use of corticosteroids can
be further delineated based on route of administration.
SYSTEMIC
Historically, reviews of the use of systemic corticosteroids have
investigated the effects of dexamethasone on BPD (treatment of
existing lung injury as well as prevention) when administered
during different time periods: early (<96 h after birth), mod-
erately early (7–14 days after birth), or late (>3 weeks after birth;
Halliday et al., 2003a,b,c). However, more recent reviews have
classiﬁed trials as early (<7 days of life) or late (≥7 days after
birth) based on timing of dexamethasone administration (Doyle
et al., 2014a,b). All of these reviews have shown that dexametha-
sone facilitates extubation, reduces the combined endpoint of
death or BPD at 28 days or 36 weeks PMA, and also reduces
the incidence of PDA and ROP. However, the meta-analyses
investigating trials where glucocorticoids have been used early
in life have also found a signiﬁcant increase in adverse long-
term neurologic outcomes, speciﬁcally cerebral palsy (Doyle et al.,
2014a). In contrast, there has been no signiﬁcant increase in
long-term neurologic outcomes detected with regard to moder-
ately early and late administration of glucocorticoids (Halliday
et al., 2003a,c; Doyle et al., 2014a). Nevertheless, the trend toward
an increase in the incidence of abnormal neurologic ﬁndings in
trials of late administration of glucocorticoids have prompted
the American Academy of Pediatrics to issue a policy statement
advising against the early use of dexamethasone and strongly
recommending caution with the routine use of dexamethasone
after 7 days of life (Watterberg, 2010). However, data from 16
RCTs extracted by Onland et al. (2009) demonstrated that mod-
erately early administration of dexamethasone (7–14 days after
birth) did not signiﬁcantly increase the combined outcome of
death or cerebral palsy and actually showed a dose dependent
decrease (6.2%) in cerebral palsy with each incremental mg/kg
increase in cumulative dexamethasone dose. Interestingly enough,
this promising dose-dependent effect on neurodevelopmental
outcome was not demonstrated in the delayed (>3 weeks) glu-
cocorticoid treatment trials. These data illustrate the potential
time-sensitive effects of dexamethasone and the need for clinicians
to balance the known impact on neurodevelopmental outcome
associated with prolonged mechanical ventilation and the devel-
opment of BPD with the risks/beneﬁts of systemic glucocorticoid
treatment.
Other investigators have suggested that a primary cortisol deﬁ-
ciency in preterm infants increases the risk of BPD which may
be amenable to early treatment with a less potent corticosteroid
such as hydrocortisone (Watterberg, 2007). A meta-analysis from
Doyle et al. (2010) evaluated eight RCT investigating the clini-
cal effects of postnatal hydrocortisone given in the ﬁrst week
of life to VLBW infants. Infants who received hydrocortisone
did not demonstrate a signiﬁcant reduction in mortality, BPD,
or cerebral palsy and actually had a signiﬁcant increase in the
incidence of gastrointestinal perforation (although this occurred
more often when indomethacin was given concurrently). Indeed
there has been emerging literature indicating that prolonged
hydrocortisone exposure can negatively impact language and
motor skills in the ﬁrst years of life (Patra et al., 2014). Ongo-
ing randomized, controlled clinical trials will no doubt help
generate data on the appropriate dose and timing of hydro-
cortisone treatment for the prevention of BPD1 (Onland et al.,
2011).
INHALED
Inhaled steroids have been examined as a therapeutic approach
to the treatment of BPD in order to promote respiratory ben-
eﬁts while minimizing systemic side effects. Studies examining
the beneﬁts of inhaled corticosteroids administered early or late
have not been able to demonstrate any impact of inhaled cor-
ticosteroids on short-term respiratory outcomes (e.g., death or
BPD at 36 weeks PMA) or longer-term clinical respiratory sta-
tus (Onland et al., 2012; Shah et al., 2012b). Additionally, inhaled
corticosteroids appear to offer no clinical advantage over systemic
steroid therapy (Shah et al., 2012a). The potential for systemic
absorption of inhaled steroids and subsequent side effects (e.g.,
growth, adrenal suppression, etc.) warrants careful consideration
before initiation of this treatment approach. Further research is
needed to evaluate the type of inhaled steroid, timing, formulation,
dosage, andmethod of administration that is most appropriate for
the prevention and treatment of BPD.
PULMONARY VASODILATORS
INHALED
It is well-recognized that infants with BPD can experience inter-
mittent episodes of hypoxia which can promote secondary pul-
monary vasoconstriction and pulmonary hypertension, adding to
the complexity of BPD (Khemani et al., 2007; Steinhorn, 2013).
This has resulted in much interest in the selective pulmonary
vasodilator nitric oxide (NO) as alterations inNOsignaling, vascu-
lar growth, and reactivity appear to play a role in the development
of BPD (MacRitchie et al., 2001; Afshar et al., 2003). In animal
models of BPD, inhaled NO promotes pulmonary angiogene-
sis, reduces inﬂammation, and decreases apoptosis and oxidant
1ClinicalTrials.gov PREMILOC trial to prevent bronchopulmonary dysplasia in very
preterm neonates. Clinical.Trials.Gov identiﬁer: NCT00623740.
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damage (Gutierrez et al., 1996; Balasubramaniam et al., 2006; Tang
et al., 2007). Three large randomized trials have been conducted
to evaluate the effect of inhaled NO on survival without BPD in
VLBW infants (Ballard et al., 2006; Kinsella et al., 2006; Mercier
et al., 2010). Only one study was able to demonstrate a mod-
est but statistically signiﬁcant beneﬁt in survival without BPD at
36 weeks PMA (Ballard et al., 2006). Furthermore, evidence from
Van Meurs et al. (2005) indicate a higher rate of mortality and
intraventricular hemorrhage (IVH) in infants weighing <1000 g
at birth who received inhaled NO. Large meta-analyses have since
been unable to ﬁnd consistent long-term improvement in mor-
tality or the incidence and severity of BPD when using inhaled
NO in preterm infants as a prevention or rescue therapy (Askie
et al., 2011; Donahue et al., 2011). Currently, there remains insuf-
ﬁcient evidence to recommend the use of inhaled NO therapy in
preterm infants who have respiratory failure for the purpose of
preventing or improving BPD, even in infants who have devel-
oped pulmonary hypertension (Kumar and Committee on Fetus
and Newborn, 2014).
SYSTEMIC
Sildenaﬁl is a selective phosphodiesterase inhibitor that increases
concentrations of cyclic guanosine monophosphate (GMP) and
thus promotes pulmonary vasodilation. Animal studies of silde-
naﬁl have shown that it promotes alveolar growth, mitigates lung
inﬂammation, and reduces pulmonary hypertension in hyperoxia-
induced lung injury models (Ladha et al., 2005; De Visser et al.,
2009). Small pilot studies have shown that sildenaﬁl reduces
pulmonary vascular pressures in infants with severe BPD with
no additional side effects (Baquero et al., 2006; Mourani et al.,
2009). Concerns do remain in recommending widespread use
in high risk preterm neonates as an increase in mortality was
found in studies of older children receiving higher doses of
sildenaﬁl (Wardle and Tulloh, 2013). However, it remains a
promising therapy and further studies are needed to elucidate
appropriate dose, formulation, and timing of administration in
neonates with BPD (especially those with secondary pulmonary
hypertension).
LATE SURFACTANT
Historically, surfactant administration has been administered
shortly after birth for the prevention and treatment of respiratory
distress syndrome (RDS). While early surfactant administration
has not been shown to signiﬁcantly impact the development
of BPD, alterations in surfactant function have been reported
in older patients with a variety of chronic lung disorders, sug-
gesting a possible beneﬁt to late surfactant administration in
the treatment of BPD (Gunther et al., 2002; Bahadue and Soll,
2012). Analysis of surfactant samples of chronically ventilated
neonates suggests that this may be due to a deﬁciency of surfac-
tant proteins (SP) B and C (Merrill et al., 2004). Multiple pilot
trials have demonstrated an increase in tracheal SP-B concen-
trations and a transient improvement in oxygenation with no
short-term side effects following late administration of exoge-
nous surfactant (Merrill et al., 2011; Keller et al., 2012). A large,
multicenter, blinded, RCT is currently underway in an extremely
low gestational age (ELGAN) cohort examining the effects of late
surfactant therapy on surfactant function and survival without
BPD2.
PREVENTION STRATEGIES
ANTIOXIDANTS
Oxygen has a unique molecular structure that is capable of
accepting free electrons generated by oxidative metabolism into
its outer ring. Hyperoxia, reperfusion, infection, ventilator-
associated inﬂammation, and inadequate antioxidant defenses
can produce reactive oxygen species (ROS) which are toxic to
living tissues. Clinical studies suggest that ROS are involved in
the pathogenesis of BPD. Plasma concentrations of ROS (allan-
toin, expired pentane, protein carbonyls, and 3-nitro tyrosine
molecules) have been shown to be signiﬁcantly elevated in the
ﬁrst week of life in infants developing BPD compared to infants
who recover without the development of signiﬁcant chronic lung
disease (Ballard et al., 2008; Poggi and Dani, 2014). A strategy
for antioxidant enzyme replacement was investigated by Davis
et al. (1997)in high risk VLBW infants. Intratracheal administra-
tion of recombinant human CuZn superoxide dismutase (rhSOD)
was associated with increased SOD levels (lung, serum, urine)
and lower levels of biomarkers of acute lung injury (Rosen-
ﬁeld et al., 1996; Davis et al., 1997). Limited follow up data in
this initial cohort did not demonstrate any difference in death,
BPD, days of mechanical ventilation, oxygen requirement, or
neurodevelopmental outcome (Davis et al., 2000). However, a
larger trial in 302 VLBW infants followed out to 1 year cor-
rected gestational age demonstrated a signiﬁcant reduction in
pulmonary morbidity (e.g., respiratory illness, emergency room
visits, hospital readmissions) in the rhSOD-treatment versus the
placebo group, suggesting that a reduction in early oxidant injury
may still impact longer-term pulmonary outcomes (Davis et al.,
2003).
CLUB (CLARA) CELL PROTEIN (CC10)
CC10 is a 10-kilodalton protein secreted by non-ciliated bronchi-
olar epithelial cells (club cells) and is one of the most abundant
proteins within the ﬂuid lining the lung epithelium (Greenough,
2008). CC10 has extensive anti-inﬂammatory properties and has
been shown tobe signiﬁcantly lower in tracheal aspirates of prema-
ture infantswho subsequently diedordevelopedBPD(Jorens et al.,
1995; Broeckaert et al., 2000; Schrama et al., 2008). Animal stud-
ies have demonstrated that administration of recombinant human
CC10 (rhCC10) upregulates SP and vascular endothelial growth
factor (VEGF) expression while improving respiratory mechanics
(Miller et al., 2007; Wolfson et al., 2008). A pilot trial conducted
in 22 VLBW infants by Levine et al. (2005) demonstrated that
intratracheal administration of rhCC10 was well-tolerated and
had signiﬁcant anti-inﬂammatory effects in the lung. No infant
followed out to 6 months corrected gestational age had any
signiﬁcant respiratory illness following treatment with rhCC10
compared to 50% in the control group. This promising treat-
ment is being further investigated in a multi-center randomized,
blinded trial evaluating survival without long-term pulmonary
2ClinicalTrials.gov TOLSURF trial of late surfactant for prevention of bronchopul-
monary dysplasia. Clinical.Trials.gov Identiﬁer: NCT01022580.
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morbidity (chronic respiratory morbidity at 1 year corrected age)
as the primary outcome3.
CONCLUSION
Decades after initially being described by Northway et al. (1967),
BPDstill remains a very important complicationof neonatal inten-
sive care. BPD is a complicated multisystem disease that carries a
signiﬁcant physical, social, and economic burden for the survivors
and their families. While multiple therapies are used routinely
either alone or in combination (potentially increasing drug–drug
interactions and associated side effects), there is insufﬁcient evi-
dence supporting short and longer-term use of many of these
agents. In fact, no single therapy has been shown to have a signiﬁ-
cant impact on the incidence or severity of BPD. Targeting single
mechanisms is unlikely to signiﬁcantly inﬂuence BPD since it is
multifactorial in nature. Future research should be focused on
establishing better biomarkers predictive of BPD and associated
longer-term chronic respiratory morbidity, developing stratiﬁca-
tion models to identify high-risk infants early on, and applying
a multimodal approach when studying various pharmacologic
interventions.
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